Rare diseases affect over 350 million patients worldwide. Unfortunately, it can take years of research and misdiagnoses before the correct rare disease is identified. This so-called "diagnostic odyssey" is not only causing patients distress and emotional turmoil, but also frustration among clinicians and an enormous financial burden on healthcare systems and associated trusts. This is the problem that Mendelian has set out to overturn.
Mendelian’s specialised screening system, dubbed MendelScreen, incorporates augmented intelligence and data analysis to produce a ranked list of likely causative disease genes based on how closely the patient’s query matches a disease. The company's platform is even more unique as it goes one step further to make "smart suggestions” regarding diagnosis, specialist referral and recommendations for further tests and analysis.
Mendelian's ultimate goal is to provide timely diagnoses for every patient suffering from a rare disease. It continually invests into its service to ensure the reports it provides are optimised for efficiency and data provision.
Steph
Company Specialist at Welcome to the Jungle
